Israeli pill shows promise for diabetes

TEL AVIV, Israel — Oramed Pharmaceuticals, the Israeli drugmaker seeking to develop the first oral pill for diabetes, said a trial on type 2 diabetes patients showed that the medicine has promising therapeutic potential.

The one-week study of 30 patients also met safety goals, the Jerusalem-based company said Thursday. Oramed plans to follow the mid-stage trial with another study later this year.

“The results we announced today give us confidence about the chances of success in a bigger trial going forward,” Chief Executive Officer Nadav Kidron said at a press conference Thursday at the Tel Aviv Stock Exchange. “We are also excited about the potential of this drug for type 1 diabetes.”

The results bring Oramed, whose stock has more than tripled in the past year, a step closer to doing something no company has ever done: develop oral insulin. The technology has eluded scientists for decades and Novo Nordisk, a Danish developer of diabetes products valued at about $104 billion, has yet to develop a pill to replace daily shots.

While Oramed is years away from a potential approval, it’s taking advantage of the growing attention to raise money. The company raised $16 million on Dec. 25, five days after it said it had successful results in an early-stage type 1 diabetes study. On Jan. 24, the company filed to raise as much as $100 million.

The market for drugs to treat diabetes is likely to grow to more than $58 billion in 2018 from $35 billion in 2012, Standard &Poor’s wrote in an October report.

Diabetes afflicted 371 million people and killed 4.8 million worldwide in 2012, according to the International Diabetes Federation. People with type 2 diabetes don’t produce enough insulin, a hormone that helps the body use or store blood sugar, or can’t use the insulin properly. The illness, the most common form of diabetes, often strikes people over the age of 40, and is tied to obesity and sedentary lifestyles.

The drugmaker’s Protein Oral Delivery, or POD, technology, is based on research by scientists at Jerusalem’s Hadassah Medical Center.

The Phase IIa trial detailed Thursday will be followed by a Phase IIb study.

More in Local News

Herald photos of the week

A weekly collection of The Herald’s best images by staff photographers and… Continue reading

Trail work by juvenile offenders builds resumes, confidence

Kayak Point trails were built out this year by groups from Denney Juvenile Justice Center.

Volunteers clean up homeless camp infested with garbage

The organization’s founder used to live and do drugs in the same woods.

Families begin relocating from public housing complex

Baker Heights is in need of repairs deemed to costly to make, and will be demolished and replaced.

Everett mayoral campaign is one of the priciest ever

Many campaign donors are giving to both Cassie Franklin and Judy Tuohy.

Arrests made in robbery-turned fatal Everett shooting

A man, 24, and woman, 18, were found at a hotel in Seattle.

3 fire departments seek levies to support emergency services

District 25 in Oso is hoping to pass its first fire levy in 22 years.

Flooding still a concern on Snohomish River

Flood warning in effect until Monday afternoon for Monroe and Tuesday morning for Snohomish.

Front Porch

JUST FOR YOUTH Build with balloons Youth in fourth grade and up… Continue reading

Most Read